AustraliaHealth

Neurizon Therapeutics (ASX:NUZ) has unveiled compelling new preclinical data regarding its lead compound, NUZ-001.

Biopharmaceutical innovator Firebrick Pharma (ASX:FRE) has secured $1.5 million in firm commitments through a strategic placement.

Paradigm Biopharmaceuticals (ASX:PAR) confirmed that 50% of the required participants have now been dosed in its PARA_OA_012 Phase 3 clinical trial.

Alterity Therapeutics (ASX:ATH) announced alignment with the US Food and Drug Administration following a pivotal Type C meeting.

Aroa Biosurgery (ASX:ARX) has achieved a clinical milestone following the completion of its randomised controlled trial for Symphony.

Reece (ASX:REH) announced a comprehensive redesign of its remuneration framework for top-tier leadership.

Lumos Diagnostics (ASX:LDX) announced a US market expansion triggered by the US FDA granting a CLIA waiver for its flagship point-of-care test, FebriDx.

4DMedical (ASX:4DX) secured CE Mark clearance for its pioneering CT:VQ software.

Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its Phase 1 clinical trial of RAD 402.

Firebrick Pharma (ASX:FRE) has secured its first-ever regulatory approval for Nasodine nasal spray.

Monash IVF Group (ASX:MVF) has appointed Birol Akdogan as its Interim CFO, effective March 26.

Clarity Pharmaceuticals (ASX:CU6) has entered into a large-scale manufacturing supply agreement with Theragenics for the production of copper-64.